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Strengths and limitations of this study
 ► The ‘Psoriasis in Adolescents’ (PIA) cohort consists 
of adolescents with psoriasis, as well as genetical-
ly predisposed and non-predisposed adolescents 
without psoriasis, from a large nationwide general 
population birth cohort in Denmark.
 ► Collected information includes clinical characteris-
tics of psoriasis, blood samples for cardiovascular/
metabolic risk factors and genetic analyses, micro-
biological swabs and data on physical and mental 
health.
 ► A major strength of the PIA cohort is the possibility 
of linking data to the birth cohort and the national 
health registries in Denmark.
 ► The cohort is limited by the relatively small size; 
however, we have clinically confirmed the psoriasis 
status.
AbStrACt
Purpose Psoriasis is a chronic inflammatory skin disease 
that frequently debuts in childhood and adolescence. 
We wished to determine environmental and genetic risk 
factors for the development of psoriasis in children and 
adolescents, as well as to investigate debut type, trigger 
factors, course of disease, nature and influence of stress 
related to both child and family and risk factors for 
comorbidity. The ‘Psoriasis in Adolescents’ (PIA) cohort 
will provide data on the relationship between psoriasis 
and, respectively, genetic disposition, early-life exposures, 
quality of life and comorbidity.
Participants The PIA cohort is nested in the large general 
population Danish National Birth Cohort (DNBC). We 
invited 390 adolescents with psoriasis and corresponding 
maternally predisposed and non-predisposed controls. 
Participants underwent an interview and a clinical 
examination consisting of a skin inspection and 
physical measurements including blood sampling and 
microbiological swabs. Additionally, four self-administered 
questionnaires on physical and mental health were 
completed.
Findings to date The final PIA cohort consists of 81 
adolescents with psoriasis, 110 parentally predisposed 
and 124 non-predisposed psoriasis-free adolescents. The 
validity of the maternally reported psoriasis status from 
the DNBC was found to be low on clinical examination 
(47.5%). In contrast, the self-reported psoriasis status of 
the DNBC mothers was clinically confirmed in 80.8% of 
the cases.
Future plans The PIA cohort offers the possibility of 
assessing the clinical characteristics, course of psoriasis 
and development of comorbidities in adolescents with 
clinically confirmed disease from a general population. 
Comparison with predisposed and non-predisposed 
controls is possible and genetic analyses are scheduled. 
We plan to invite the participants for a follow-up in 5–10 
years. Furthermore, we plan to include newly diagnosed 
adolescents with psoriasis from the 18-year DNBC follow-
up. All information is linkable on the individual level with 
data from the DNBC and nationwide registries in Denmark.
IntroduCtIon
Psoriasis is a chronic inflammatory skin 
disease with a complex multifactorial aeti-
ology affecting approximately 3% of the 
western population.1 Both genetics and envi-
ronmental factors influence the onset of 
disease. In twin studies, it has been shown 
that up to 70% of the risk of psoriasis can be 
explained by genetics; furthermore, having 
one parent with psoriasis yields a 30% risk of 
the child also having psoriasis, while psori-
asis in both parents increases the risk up to 
50%–65%.2–4 Several genetic risk loci have 
been identified in genome-wide associa-
tion studies, including the PSORS1–9 loci. 
PSORS1 is located in the major histocom-
patibility complex of chromosome 6 p; the 
HLA-Cw6 allele coded in this region has 
been shown to be particularly important and 
it is associated with an early debut of psori-
asis.5 6 Known environmental risk factors or 
‘trigger factors’ are physical trauma (the 
Koebner phenomenon), streptococcal throat 
infection, psychological stress, certain drugs, 
smoking and obesity.7–10 The age of onset is 
bimodal with peaks around 16–22 and 57–60 
years; however, around one-third of patients 
with psoriasis have had their debut at the age 
of 16 years.6 9 In children and adolescents, the 
overall prevalence has been shown to be 0.7% 
with a linear increase from 0.1% at the age of 
1 year to 1.2% at 18 years.11 The diagnosis of 
psoriasis is mostly clinical and based on skin 
appearance, although a skin biopsy supports 
the diagnosis. In children and adolescents, 
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Figure 1 Flowchart showing the recruitment process and 
classification of the adolescents from the Danish National 
Birth Cohort in the Psoriasis in Adolescents cohort.
psoriasis can be difficult to diagnose because of mild and 
overlapping symptoms (eg, atopic and seborrheic derma-
titis) and a lack of validated clinical examination-based 
diagnostic criteria.3 12–14 The most common type of 
psoriasis, plaque psoriasis, manifests itself as well-demar-
cated red and scaly plaques, with itch and discomfort as 
common complaints.15 Psoriasis severely affects quality of 
life with an impact comparable to other major diseases, 
not only in adults but also in children and adoles-
cents.16 17 In adults, psoriasis has been shown to be asso-
ciated with a wide range of comorbidities, predominantly 
cardiovascular and metabolic diseases, and also depres-
sion and anxiety and autoimmune disorders including 
inflammatory bowel disease.18–22 Previous studies on 
children and adolescents with psoriasis have found some 
of these comorbidities, or risk factors thereof, to be 
increased.11 23–26 Since these studies have mainly been 
done in highly selected hospital-treated populations, with 
small sample sizes, or by retrospectively reviewing, for 
example, patient records, we wished to investigate paedi-
atric psoriasis in a more general population, and also 
to include psoriasis-free controls for comparison, with 
the possibility of prospective data collection.11 23–49 We 
therefore established a well-characterised clinical cohort 
nested in a large, nationwide birth cohort in Denmark 
in order to investigate the clinical characteristics, trigger 
factors, comorbidities and related risk factors and geno-
type of paediatric psoriasis. Our clinical cohort consists 
of adolescents with psoriasis, as well as predisposed and 
non-predisposed psoriasis-free controls: the ‘Psoriasis in 
Adolescents’ (PIA) cohort.
Cohort deSCrIPtIon
Study population
The PIA cohort is a clinical cohort of adolescents (WHO: 
age 10–19 years) with psoriasis, adolescents with no psori-
asis, but with genetic predisposition, and adolescents with 
no psoriasis nor predisposition. The clinical study popu-
lation is nested in the large, nationwide birth cohort in 
Denmark—the Danish National Birth Cohort (DNBC).50 
The DNBC was established from 1996 to 2002 and consists 
of the offspring of approximately 100 000 expecting 
mothers recruited during pregnancy from the general 
Danish population. The mothers were included at the 
first antenatal care visit at the general practitioner and 
candidates were required to speak Danish well enough 
to participate in telephonic interviews. The mother and 
child have since been followed up with interviews and 
online questionnaires at child-age 6 months, 18 months, 
7, 11 and 14 years, and an 18-year follow-up is currently 
undertaken.
We invited adolescent DNBC participants to join the PIA 
cohort based on three selection criteria: (1) adolescents 
with maternally reported psoriasis, (2) adolescents with 
no psoriasis but with maternal predisposition to psori-
asis and (3) adolescents with no psoriasis nor maternal 
predisposition.
The adolescents with psoriasis were identified using 
version 2 of the 11-year DNBC follow-up questionnaire to 
the mothers. The majority of the participating mothers 
received this version. In this, the mothers were asked: 
“Has your child ever had an outbreak of the disease psori-
asis?” This information allowed us to identify adolescents 
with psoriasis based on their mothers’ self-reported diag-
nosis. Adolescents with no psoriasis, but with maternal 
predisposition, were identified using the mother’s first 
telephonic interview during pregnancy, where she was 
asked the following series of questions: “Have you ever 
had any skin disease?” → “Was the skin disease diagnosed 
by a doctor?” → “What kind of skin disease?” → “Psori-
asis”. Accordingly, adolescents with no psoriasis, nor 
maternal predisposition, were identified.
recruitment process
In the DNBC, 390 adolescents with maternally reported 
psoriasis were eligible for invitation to participate in our 
clinical study and all of these adolescents were invited. 
We also identified approximately 2500 mothers with 
psoriasis, and out of these mother–child pairs and the 
entire remaining DNBC population, we correspondingly 
invited a similar number of maternally predisposed (391) 
and non-predisposed psoriasis-free adolescents (384) by 
random selection (figure 1).
From 2016 to 2017, we sent out invitational letters to 
the mother–child pairs. Adolescents of legal age (≥18 
years) were addressed directly. The invitational letter 
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contained a self-addressed stamped envelope for prelim-
inary declaration of interest to participate. To maximise 
the response rate, we invited all adolescents with mater-
nally reported psoriasis twice, and participants were 
compensated for mileage expenses and the adolescents 
were offered a gift card (250 DKK). Interested mothers 
and adolescents were contacted by telephone and a date 
for interview and clinical examination at one of three 
locations in Denmark were scheduled. These locations 
were the Department of Dermatology and Allergy at 
Herlev and Gentofte Hospital, the Department of Derma-
tology at Aarhus University Hospital and dermatological 
private practice NORD in Aalborg. Interviews and clin-
ical examinations were undertaken from January 2016 to 
June 2017.
For adolescents under the legal age, it was mandatory to 
be accompanied by a minimum of one parent/guardian 
and consent from both parents/guardians was required; 
however, a letter of attorney from the absent parent/
guardian was accepted. Participants were included only 
after oral and written consent.
Out of the 1165 invited adolescents from the DNBC, the 
overall positive response rate was 32.0%, and we managed 
to include 27.1% of the total invited adolescents. Spec-
ified by invitational group, we included 115 (29.5%) of 
the adolescents with maternally reported psoriasis, 120 
(30.7%) of the adolescents with no psoriasis but with 
maternal predisposition and 81 (21.1%) of the adoles-
cents with no psoriasis nor predisposition.
Interview
During an interview on the scheduled day of visit, the 
investigator completed a questionnaire by asking the 
adolescent a predefined series of questions. In order to 
minimise recall bias, the accompanying parent/guardian 
was allowed to help. The questionnaire consisted of 
psoriasis-specific questions and more general health-re-
lated questions. Regarding psoriasis, the adolescents 
were asked about their own psoriasis history and 
possible symptoms of psoriasis, family history of psoriasis 
and psoriatic arthritis, possible trigger factors for psori-
asis (eg, stress, medication or throat infections) and, if 
relevant, present and ever psoriasis-specific treatment. 
Adolescents with psoriasis were asked about age and sites 
of psoriasis at debut, and the primary clinical phenotype 
was characterised. The general part of the questionnaire 
covered comorbidities, particularly cardiovascular and 
metabolic disease, atopic diseases and inflammatory 
bowel disease, as well as history of diaper rash in infancy. 
Additionally, information on smoking, alcohol use and 
psychosocial areas was included. Finally, general medi-
cation use was recorded. In addition to the research 
questionnaire completed by the investigator, the adoles-
cents completed four self-administered questionnaires. 
These questionnaires concerned depression (Major 
Depression Inventory),51 general anxiety (The Gener-
alized Anxiety Disorder 7-Item Scale),52 activity in daily 
life (ad hoc questionnaire) and skin-related quality of 
life (The Children’s Dermatology Life Quality Index).53 
A subgroup of the adolescents also participated as 
members of a focus group in the construction and vali-
dation of a paediatric psoriasis-specific quality of life 
assessment tool.
Clinical examination
Regardless of psoriasis status in the DNBC, the clinical 
examination of the adolescents included a thorough 
inspection of the skin and nails for signs of psoriasis and 
other skin diseases, and we also recorded the Tanner 
stage.54 55 The clinical examination decided the final psori-
asis status of the adolescents irrespective of the status in 
the DNBC. Among adolescents with clinically confirmed 
psoriasis, the disease severity was assessed and scored 
using both Psoriasis Area and Severity Index (PASI) and 
body surface area (BSA). PASI assesses redness, scaling, 
infiltration and area of the involved skin, whereas BSA 
includes only the area.56 The distribution of psoriasis was 
noted and marked on a diagram and the present psoriasis 
phenotype was recorded. The clinical diagnosis of psori-
asis in the adolescents was supported by a history of physi-
cian-diagnosed psoriasis and a predefined set of criteria 
on paediatric psoriasis from a Delphi consensus by the 
International Psoriasis Council.14 These criteria consist 
of either one major criterion or three minor criteria and 
we used them to support our psoriasis diagnosis based 
on present examination or medical history. Adoles-
cents fulfilling these requirements are termed ‘clinically 
confirmed’. Psoriasis in the family was confirmed based 
on a history of physician-diagnosed psoriasis and clinical 
appearance where possible. The adolescents were cate-
gorised as predisposed if either mother or father had 
psoriasis.
Physical measurements, blood samples and microbiological 
swabs
For all the clinically examined adolescents, we measured 
blood pressure and pulse using a Microlife BP A3 Plus 
automatic blood pressure monitor. Height, weight 
and hip and waist circumferences were also recorded. 
The majority of the adolescents performed spirometry 
testing with an EasyOne Volksspirometer spirometer. Blood 
samples were collected to measure haemoglobin A1c 
(2 mL blood), high-sensitivity C-reactive protein, choles-
terol (high-density lipoprotein (HDL), low-density lipo-
protein (LDL), very-low-density lipoprotein (VLDL) and 
total) and triglycerides (3 mL blood). All analyses were 
done per standard protocol at Department of Clinical 
Biochemistry, Herlev and Gentofte Hospital. Blood was 
also collected for subsequent DNA (6 mL blood) and RNA 
(3 mL blood) analyses, in addition to serum (4 mL blood) 
that was stored in a biobank for potential later analyses. 
Furthermore, microbiological swabs (COPAN eSwab) were 
taken from the throat and perineum, and the samples 
were analysed by standard methods at the Department of 
Clinical Microbiology, Herlev and Gentofte Hospital.
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Power calculation and data management
Prior to study start, a power calculation was performed. We 
used a hypothetical case–control study, assessing whether 
overweight (exposure 10%) is associated with psoriasis 
in the adolescents, as a model.57 Cases were adolescents 
with psoriasis and the controls were adolescents without 
psoriasis. To detect an OR of 2.5 with 80% power and an 
α-level of 5%, it was necessary to estimate a minimum 
sample size of 302 (151 cases and 151 controls).
All data from the clinical examination, the general 
research questionnaire, the four self-administered ques-
tionnaires and the laboratory results were entered in a 
secure REDCap database.58 To ensure data consistency, all 
information was entered twice by two separate individuals.
Patient and public involvement statement
Patients were first involved at the time of receiving the 
invitational letter, but the invited families were active in 
the DNBC since inclusion during pregnancy. Our partic-
ipants were not directly involved in the design of the PIA 
cohort. On completion of the study, all participants will 
receive a concluding letter with study findings and infor-
mation on future perspectives of the research.
FIndIngS to dAte
Final cohort and validity of the dnbC psoriasis status
The final psoriasis grouping of the adolescents included 
in the PIA cohort was determined by the clinical exam-
ination and medical history, irrespective of the a priori 
designations recorded in the DNBC: (1) adolescents with 
clinically confirmed psoriasis, (2) adolescents with no 
psoriasis but with parental predisposition to psoriasis and 
(3) adolescents with no psoriasis nor parental predisposi-
tion (figure 1).
After interview and clinical examination, the included 
adolescents were classified as follows: 81 adolescents with 
clinically confirmed psoriasis, 110 adolescents with no 
psoriasis but with parental predisposition to psoriasis and 
124 adolescents with no psoriasis nor parental predisposi-
tion. As shown in the flowchart (figure 1), we reclassified 
a substantial number of the included adolescents, as we 
found some misclassification in the DNBC psoriasis status 
of both the adolescents and the mothers.
The majority of the adolescents were of Scandina-
vian descent. The median (range) age in the three 
groups were 16.0 (13.5‒18.5), 15.3 (13.5‒18.0) and 15.6 
(13.8‒18.4) years, respectively, for the adolescents with 
psoriasis, the non-predisposed and the predisposed psori-
asis-free adolescents. The sex ratio was roughly even, with 
a slight male predominance in the psoriasis group (53.1% 
vs 44.6% vs 44.4%). The adolescents with psoriasis were 
found to have mild disease on examination with a median 
PASI of 1.2 (range 0.1‒11.4) and a median BSA of 1.0% 
(range 0.1‒12%). This was reflected in the used treat-
ments with topical corticosteroids of moderate-to-high 
potency being the most commonly used.
On basis of the clinical examination, secondarily we 
had the opportunity to perform a validation of the DNBC 
information on psoriasis status of both the mothers and 
the adolescents. For practical reasons, we screened the 
adolescents with maternally reported psoriasis living 
in the western part of Denmark for likelihood of actual 
psoriasis on the first telephonic contact. However, all 
adolescents with maternally reported psoriasis included 
at Herlev and Gentofte Hospital were unscreened and 
therefore totally unselected. Unexpectedly, in this latter 
unselected group of adolescents, we could only confirm 
the diagnosis of psoriasis with a debut before the 11-year 
follow-up in 28 out of 59 adolescents (47.5%). In most 
cases, the adolescents had atopic dermatitis or unspeci-
fied eczema instead. The telephonic screening explains 
why the validity of the maternally reported psoriasis status 
appears to be higher in the flowchart, with 70 confirmed 
psoriasis cases out of 114 examined adolescents (61.4%, 
1 adolescent was excluded), since this number also 
includes the actively selected group from the western 
part of Denmark. Regarding the mothers, out of the total 
120 mothers with self-reported psoriasis at time of inclu-
sion during pregnancy, we could confirm the diagnosis 
with a debut before inclusion in the DNBC in 97 of them 
(80.8%).
Strengths and limitations
Our PIA cohort offers the opportunity to assess the 
course and clinical phenotype of adolescent psoriasis in 
a general population. The diagnosis of psoriasis has been 
confirmed clinically, and even though no recognised 
clinical examination-based criteria on paediatric psori-
asis exist we supported our diagnosis by a predefined set 
of criteria.12 We have data on possible trigger factors for 
psoriasis and medical history regarding a range of other 
diseases and known comorbidities. The cohort includes 
genetically predisposed controls and controls with no 
predisposition to compare with, and we plan to collect 
data prospectively in future follow-ups. Furthermore, the 
clinical characteristics are complemented by laboratory 
data on cardiovascular and metabolic risk factors and 
microbiological carrier status. Additionally, genetic anal-
yses, including gene–environment analysis, will be carried 
out to further clarify the complex aetiology of psoriasis, 
its phenotypes and trigger factors. Finally, we seek to 
investigate the impact of an early debut of psoriasis on 
quality of life and to develop a paediatric psoriasis-spe-
cific assessment tool. A great advantage of the PIA cohort 
is the possibility of linking data from every follow-up of 
the DNBC and also linkage to routinely collected health 
data in national registries. The DNBC contains data on 
a large variety of subjects relating to the child’s envi-
ronment and development rarely found in the national 
registries, including information on home environment, 
diet, sleep, allergy, exercise, mental health and parental 
predispositions. All inhabitants in Denmark are assigned 
a unique 10-digit personal identification number in the 
Danish Civil Registration System that allows linkage on 
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the individual level with the DNBC and other national 
registries, for example, the Danish National Patient 
Registry and the Danish National Prescription Registry, 
respectively, containing information on all hospital diag-
noses and prescribed medication in Denmark.50 59–61
Our cohort is limited by relatively small size; however, 
we validated the self-reported psoriasis status of the 
DNBC for both the adolescents and the mothers. The 
small sample size could make some associations and 
differences more difficult to show, and furthermore, even 
though the adolescents are from an unbiased general 
population cohort the risk of selection bias should still 
be kept in mind when generalising any findings from 
the PIA cohort. The data from our cohort show that 
the self-reported psoriasis status of the mothers in the 
DNBC has a high validity comparable to what has previ-
ously been shown in Norway.62 This is in contrast with the 
low validity of the maternally reported psoriasis in their 
offspring. The main reasons for this discrepancy are prob-
ably that only the mothers were asked specifically about 
physician-diagnosed psoriasis and that psoriasis in child-
hood can be difficult to diagnose due to mild and over-
lapping symptoms.13 This emphasises the importance of 
asking as specific and unambiguous questions as possible 
when collecting self-reported data. Importantly, we plan 
to invite and add newly diagnosed adolescents with psori-
asis to the PIA cohort using the ongoing 18-year follow-up 
of the DNBC. Here, the adolescents are asked specifically 
about physician-diagnosed psoriasis, which expectedly 
will increase the validity of this information.
CollAborAtIon
We are interested in collaborations with other research 
groups having data related to psoriasis in children and 
adolescents. Please find data sharing statement below.
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